Bayer’s Eylea market grip set to slip as Alvotech biosimilar closes in
Alvotech has moved one step closer to entering the Eylea (aflibercept 2 mg) biosimilar market, after a European Medicines Agency…
News
Harbour BioMed partners Otsuka on new T-cell therapy
EC approves argenx’s efgartigimod alfa for CIDP treatment
Madrigal poised to enter European MASH market after CHMP endorsement
Novartis’ ribociclib approved in Canada for early breast cancer
FDA cell and gene therapy director exit increases ‘volatility’ for sector
NSW government invests $13.39m in life-changing therapies
DoH – Abu Dhabi and Sanofi link for vaccine development
